Procaps Group Sa Stock Today
| PROCW Stock | USD 0.01 0 17.29% |
Performance9 of 100
| Odds Of DistressOver 59
|
Procaps Group is selling for under 0.011 as of the 25th of November 2024; that is 17.29 percent down since the beginning of the trading day. The stock's lowest day price was 0.011. Procaps Group has over 59 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Procaps Group SA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of February 2023 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of September 2021 | Category Healthcare | Classification Health Care |
Procaps Group, S.A. develops, manufactures, and markets over-the-counter and prescription drugs, nutritional supplements, and clinical solutions. The company was founded in 1977 and is based in Luxembourg City, Luxembourg Procaps Group is traded on NASDAQ Exchange in the United States.. More on Procaps Group SA
Moving against Procaps Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Procaps Stock Highlights
| Founder Chairman | Ruben Minski | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Procaps Group can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Procaps Group's financial leverage. It provides some insight into what part of Procaps Group's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Procaps Group SA (PROCW) is traded on NASDAQ Exchange in USA. It is located in 9 Rue de Bitbourg, Luxembourg, Luxembourg, 1273 and employs 5,500 people. Procaps Group is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
Procaps Group generates positive cash flow from operations, but has no cash available
Check Procaps Group Probability Of Bankruptcy
Procaps Group Historical Income Statement
Procaps Stock Against Markets
Procaps Group Corporate Management
| Camilo Camacho | Chief Officer | Profile | |
| Sergio Gomez | Chief Officer | Profile | |
| Patricio Vargas | Global Officer | Profile | |
| Carlos Russo | Head Finance | Profile |
Additional Tools for Procaps Stock Analysis
When running Procaps Group's price analysis, check to measure Procaps Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procaps Group is operating at the current time. Most of Procaps Group's value examination focuses on studying past and present price action to predict the probability of Procaps Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procaps Group's price. Additionally, you may evaluate how the addition of Procaps Group to your portfolios can decrease your overall portfolio volatility.